Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 6/20 | 0.62 |
| ▸ | MAOA | P21397 | 3/20 | 0.56 |
| ▸ | MAOB | P27338 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.55 |
| ▸ | IGF2R | P11717 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708383 | 1.00 | XDH (0.62) | XDHAPPMAOAMAOBGAA | |
| SCHEMBL8854590 | 0.92 | APP (0.74) | XDHAPPGAAMAPTRAB9A | |
| SCHEMBL709523 | 0.87 | CYP1A1 (0.57) | MAOAMAOBGAAMAPTRAB9A | |
| SCHEMBL709522 | 0.87 | CYP1A1 (0.57) | MAOAMAOBGAAMAPTRAB9A | |
| SCHEMBL3222154 | 0.82 | APP (0.74) | APPMAOAMAOBGAAMAPT | |
| SCHEMBL3222176 | 0.82 | APP (0.74) | APPMAOAMAOBGAAMAPT | |
| SCHEMBL21798699 | 0.82 | XDH (0.77) | XDHAPPMAOAMAOBGAA | |
| SCHEMBL709202 | 0.82 | PTGS1 (0.49) | APPGAAMAPTRAB9ANFE2L2 | |
| SCHEMBL709201 | 0.82 | PTGS1 (0.49) | APPGAAMAPTRAB9ANFE2L2 | |
| SCHEMBL710996 | 0.81 | KRAS (0.58) | GAAMAPTRAB9AEGFRNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124625-B2 | enhancing the expression of apoAI; prevention or therapy of dislipidemia | SHIONOGI & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8053445-B2 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20090036457-A1 | Utilities of olefin derivatives | YAMAMORI TERUO | 2009-02-05 | — | — | US | disclosed |
| US-20040242615-A1 | Utilities of olefin derivatives | SHIONOGI & CO., LTD. (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242615-A1 | Utilities of olefin derivatives | APOL1, NR1H2, APOB | XDH 401/4885APP 837/4885MAOA 353/4885 |
| US-20090036457-A1 | Utilities of olefin derivatives | APOL1, APOB, NR1H2 | XDH 269/4885APP 628/4885MAOA 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.